<DOC>
	<DOCNO>NCT03096041</DOCNO>
	<brief_summary>Auriculotherapy complementary medicine , side effect , without contraindication , inexpensive restrictive.Its efficacy find several test especially treatment intraoperative pain . It remain controversial indication . Evaluation value auriculotherapy often difficult methodological limitation trial conduct . In daily practice , auriculotherapy propose improve articular pain patient treat AA . This Phase III study aim validate approach .</brief_summary>
	<brief_title>Phase 3 Study Randomized Evaluating Efficacy Auriculotherapy Patients With Musculoskeletal Pain Aromatase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Musculoskeletal Pain</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Patient 18 year age Patients antiaromatases adjuvant treatment breast cancer Menopausal woman Treatment aromatase inhibitor ( antiaromatase , AA ) initiate 3 month Musculoskeletal pain appear increase AA : Overall pain score QCD â‰¥3 ( scale 0 10 ) Pain least 2 site Pain least 3 month History radiotherapy / adjuvant chemotherapy authorize Patients may receive tamoxifen Patient affiliate social security system Patient master French language able complete evaluation questionnaire Free Informed Consent Patients already undergone treatment auriculotherapy indication Patient benefiting time PNCAVT ( acupuncture homeopathy ) musculoskeletal pain Wearing hearing aid hinder placement semipermanent needle ( ASP ) Wearing valve prosthesis Patient guardianship unable give inform consent Patient unable undergo medical followup geographical , social psychopathological reason</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>auriculotherapy</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>adjuvant treatment</keyword>
</DOC>